Affiliation:
1. Cytology Department Royal Surrey NHS Foundation Trust Guildford UK
Abstract
AbstractWe present a case report of a 76‐year‐old male with a histologically confirmed KRAS mutated, thyroid transcription factor 1 (TTF1) positive, grade 1, mucinous adenocarcinoma with cytologically difficult to interpret lymph node metastasis showing loss of TTF1 expression and overlapping features with goblet cell hyperplasia. The case highlights the importance of molecular testing in aiding diagnosis and guiding treatment of non‐small cell lung carcinomas (NSCLC).
Reference10 articles.
1. Lymph node micrometastasis in non–small cell lung cancer
2. Molecular Detection of Lymph Node Metastases in Lung Cancer Patients Using the One-Step Nucleic Acid Amplification Method:Clinical Significance and Prognostic Value
3. Staging lung cancer: role of endobronchial ultrasound
4. Targeted therapies for lung cancer American Lung Association.2022Accessed February 2024.https://www.lung.org/lung‐health‐diseases/lung‐disease‐lookup/lung‐cancer/treatment/types‐of‐treatment/targeted‐therapies
5. Can Targeted Therapy for KRAS Mutations Double as Part of Immunotherapy National Cancer Institute.2022Accessed February 2024. KRAS‐Targeted Therapy Doubles as Component of Immunotherapy – NCI (cancer.gov).